These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 21708402

  • 1. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC.
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [Abstract] [Full Text] [Related]

  • 2. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [Abstract] [Full Text] [Related]

  • 3. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC.
    Cancer; 2012 Jan 01; 118(1):91-100. PubMed ID: 21717433
    [Abstract] [Full Text] [Related]

  • 4. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
    Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW.
    Cancer Res; 2004 Aug 15; 64(16):5882-90. PubMed ID: 15313933
    [Abstract] [Full Text] [Related]

  • 5. New tumor markers: CA125 and beyond.
    Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.
    Int J Gynecol Cancer; 2005 Aug 15; 15 Suppl 3():274-81. PubMed ID: 16343244
    [Abstract] [Full Text] [Related]

  • 6. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
    Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM.
    PLoS One; 2015 Aug 15; 10(3):e0121112. PubMed ID: 25799488
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M.
    Arch Gynecol Obstet; 2013 Oct 15; 288(4):859-65. PubMed ID: 23564055
    [Abstract] [Full Text] [Related]

  • 8. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V.
    Gynecol Oncol; 2011 Jun 01; 121(3):487-91. PubMed ID: 21420727
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov 01; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 10. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian Cancer Study Group, Obermair A.
    Gynecol Oncol; 2013 Jun 01; 129(3):467-71. PubMed ID: 23500084
    [Abstract] [Full Text] [Related]

  • 11. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
    Høgdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, Risum S, Lundvall L, Yip C, Pedersen AT, Hartwell D, Lomas L, Høgdall EV.
    Gynecol Oncol; 2011 Nov 01; 123(2):308-13. PubMed ID: 21855971
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.
    Gynecol Oncol; 2013 Oct 01; 131(1):52-8. PubMed ID: 23891789
    [Abstract] [Full Text] [Related]

  • 13. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C.
    PLoS One; 2020 Oct 01; 15(10):e0240418. PubMed ID: 33075095
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S.
    Pathol Oncol Res; 2018 Oct 01; 24(4):739-744. PubMed ID: 29520570
    [Abstract] [Full Text] [Related]

  • 15. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.
    Ginekol Pol; 2015 Feb 01; 86(2):88-93. PubMed ID: 25807831
    [Abstract] [Full Text] [Related]

  • 16. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.
    Diagn Pathol; 2013 Jan 23; 8():11. PubMed ID: 23343214
    [Abstract] [Full Text] [Related]

  • 17. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May 23; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 18. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.
    Int J Gynecol Cancer; 2016 Jan 23; 26(1):43-51. PubMed ID: 26588231
    [Abstract] [Full Text] [Related]

  • 19. Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass.
    Grenache DG, Heichman KA, Werner TL, Vucetic Z.
    Clin Chim Acta; 2015 Jan 01; 438():358-63. PubMed ID: 25283731
    [Abstract] [Full Text] [Related]

  • 20. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A, Mohamed MR, Ali MA, Abd El-Magied MH, Helal AM.
    Asian Pac J Cancer Prev; 2016 Jan 01; 17(1):323-33. PubMed ID: 26838232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.